U.S. Markets open in 8 hrs 33 mins

RUBIUS THERAPEUT. DL-,001 (5RT.DU)

Dusseldorf - Dusseldorf Delayed Price. Currency in EUR
Add to watchlist
18.10+0.20 (+1.12%)
At close: 7:00PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close17.90
Open18.20
Bid18.10 x 0
Ask18.40 x 0
Day's Range18.00 - 18.50
52 Week Range3.54 - 26.60
Volume130
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Rubius Therapeutics Appoints Dannielle Appelhans as Chief Operating Officer

    CAMBRIDGE Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the appointment of Dannielle Appelhans as chief operating officer, effective August 9, 2021. She will oversee corporate strategy and technical operations. “Danniel

  • Insider Monkey

    11 Best Pharma and Biotech Stocks to Buy According to Jim Simons’ Euclidean Capital

    In this article, we will discuss the 11 best pharma and biotech stocks to buy according to Jim Simons’ Euclidean Capital. If you want to skip our detailed analysis of Simons’ history, investment philosophy, and hedge fund performance, go directly to the 5 Best Pharma and Biotech Stocks to Buy According to Jim Simons’ Euclidean […]

  • GlobeNewswire

    Rubius Therapeutics to Announce Second Quarter 2021 Financial Results

    CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results on Monday, August 9, 2021, before market open. The company will not be hosting a teleconference in conjunction wi